# Nuclide record lu177-radioligand-therapy (technology). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/technologies/lu177-radioligand-therapy/>
  a schema:MedicalTherapy ;
  nuclide:kind "technology" ;
  schema:identifier "lu177-radioligand-therapy" ;
  schema:name "Lutetium-177 radioligand therapy"@en ;
  schema:alternateName "177Lu"@en, "Lu-177"@en, "Lutetium-177"@en ;
  schema:description "Cancer-seeking molecules carrying the radioactive metal lutetium-177, which delivers short-range radiation to tumours it binds; approved for neuroendocrine tumours and prostate cancer."@en ;
  schema:url <https://nuclide.cc/technologies/lu177-radioligand-therapy/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Lutetium-177> ;
  schema:citation <https://en.wikipedia.org/wiki/Lutetium-177> ;
  nuclide:status "approved" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/therapy-isotope-supply-chain/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/>, <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/lutathera/> ;
  nuclide:trials <https://nuclide.cc/trials/nct06184035/>, <https://nuclide.cc/trials/nct05547061/> ;
  nuclide:dependsOn <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/therapy-isotope-supply-chain/> .